Drug data last refreshed 2d ago
RENAMIN W/O ELECTROLYTES is an injectable amino acid formulation approved in 1976 for parenteral nutritional support in patients with muscle wasting and metabolic stress. It provides essential and non-essential amino acids without electrolytes, making it suitable for renal and other specialized patient populations. The mechanism relies on amino acid supplementation to support protein synthesis and preserve lean body mass across diverse indications.
Product is in LOE-approaching phase with competitive pressure at 30%, indicating limited growth opportunities and potential team consolidation ahead.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
The Effects of a Dialysis-Specific Formula Rich in Branched-Chain Amino Acids, Omega-3, and Dietary Fiber on Nutritional Status
Effect of Amino Acids on Hepatic Fat Content in Adolescents (AMINOS Study)
The Glucagonotropic Effect of Amino Acids in Humans
Additional Dietary Large Neutral Amino Acids (LNAA) for Improved Symptoms in Adult Classical Phenylktonuria (PKU)
Bioavailability of Plant Protein Amino Acids
Worked on RENAMIN W/O ELECTROLYTES at Baxter? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moRENAMIN offers limited career growth due to its LOE-approaching status and zero linked job openings, indicating a mature, stable portfolio product with smaller commercial teams. Roles are heavily focused on defending market share, managing reimbursement complexity, and optimizing operations rather than driving innovation or expansion.